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Health care costs in the United States are rising at an alarming rate. Although 
much of the cost of care is dependent on the decisions of care providers, providers remain 
largely unaware of those costs. Legislators have passed initiatives aimed at increasing 
cost transparency, but the impact of cost transparency on the cost of care is uncertain. 
The purpose of this study was to systematically review trials investigating the 
impact of cost transparency on the cost of care delivery, identify the factors likely to 
increase the effectiveness of such interventions, and suggest directions for future 
research. 
We searched the Scopus database for relevant studies published up to November 
2014. After identifying potentially relevant studies, we performed additional searches for 
publications citing or cited by the selected studies. This process was repeated until no 
additional studies were identified. Key characteristics of relevant studies were extracted 
for analysis. 
We screened a total of 4,906 articles, 23 of which were included in the final 
analysis. We identified timing (education prior to the decision vs. feedback following the 
decision) and medium (electronic vs. nonelectronic) of communication as key factors 
impacting the effectiveness of the cost transparency intervention. One hundred percent (9 
of 9) of “postorder feedback” studies resulted in decreased costs, whereas only 54% (7 of 
13) of studies in which cost was communicated prior to the clinical decision (“pre-order 
education” studies) lowered the cost of care delivery. Eighty-eight percent (14 of
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16) of nonelectronic studies reduced costs; 29% (2 of 7) of electronic studies reduced 
costs.  
Cost transparency can be an effective strategy to reduce utilization of expensive 
tests or therapies. Intervention strategies that employ nonelectronic media for 
communication of financial information to providers and that communicate postdecision 
feedback may be most likely to succeed. The trend in current publications suggests that 
health care providers may be moving toward the less effective methods of cost 
transparency, which could hamper cost containment efforts. The strength of these 
observations is limited by the absence of prospective studies that directly compare the 
effectiveness of various cost transparency intervention methods. Future studies are 
needed to verify these findings and to determine the impact of cost transparency in new 
cost-centric organizations and incentive structures. 
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BACKGROUND 
Rapidly rising health care costs are one of the major challenges facing the United 
States. Factors including consumer insulation from direct costs and a fee-for-service 
provider reimbursement structure have driven costs to 18% of the U.S. gross domestic 
product.1 Costs associated with care delivery are, in general, poorly understood. 
Physicians remain largely unaware of costs even in situations where the cost is 
uncomplicated, such as the price of medications.2 In an effort to slow the rate of cost 
increases, legislators have put forth initiatives to increase cost transparency, which, 
presumably, would provide clinicians with the information necessary to ensure that only 
high value care is delivered to the patient.3,4 The effects of cost transparency 
interventions on resource utilization and the cost of care delivery are unclear. The most 
recent systematic review5 on the topic was published in 1997 and included only six 
studies, all of which were determined to have significantly altered provider behavior and 
reduced the cost of care. Since that time, additional studies have been published with 
mixed results. Investigators have pointed out some of the differences in the studies, such 
as setting or the object of the cost (e.g., laboratory test, pharmaceuticals, etc.), that may 
have led to the differing outcomes, but no clear pattern has emerged to explain why cost 
transparency reduces the cost of care in some instances but has no impact in others. The 
objective of our present study was to examine the impact of cost transparency on the cost 
of care delivery, identify factors that contribute to effective cost containment, and suggest 
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directions for future research. A description of our systematic review of the medical 




Due to the interdisciplinary nature of our research topic, which covers clinical 
medicine, economics, and behavioral sciences, we selected Scopus as the database for our 
literature search. In collaboration with an experienced librarian, we searched the Scopus 
database for terms related to the following concepts: health care cost; cost control; health 
care provider; provider practice patterns. The exact search strategy used is provided in 
Appendix 1. Search results were limited to primary research articles published in the 
English language. The latest search was performed on November 5, 2014. 
Inclusion and exclusion criteria 
We defined cost transparency as any communication to the health care provider of 
actual or relative costs (i.e., costs incurred by or charged to the provider, payer, or 
patient) associated with patient care. Our inclusion criteria were as follows: peer-
reviewed primary manuscript; evaluation of the impact of cost transparency on the cost of 
care delivery or utilization; performed in a real-world clinical setting (as opposed to using 
written case studies or standardized patients); targeted licensed practitioners for the 
intervention. We excluded studies that were not published in the English language or 
used surrogate measures (e.g., length of hospital stay) for cost transparency. We also 
chose to exclude any study in which cost transparency was only part of a broader 
intervention in which clinical guidance was communicated in addition to financial 
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information and the effects of the cost-related communication could not be distinguished 
from those of other aspects of the intervention. 
Study selection 
Two authors independently reviewed the titles and abstracts of the identified 
studies and labelled each as “potentially relevant” or “irrelevant” based on the inclusion 
and exclusion criteria. The same two authors then performed additional database searches 
for articles that cited or were cited by potentially relevant studies. They repeated this 
process until no additional studies were deemed to be potentially relevant, after which 
they independently reviewed the full text of all potentially relevant studies. We measured 
interrater agreement using Cohen’s unweighted κ statistic. Disagreements between 
reviewers were resolved by discussion. 
Data extraction 
Two authors independently reviewed the full text of selected manuscripts and 
extracted information on trial design, intervention medium, intervention timing, and 
outcome. The options for each category were, respectively: experimental vs. quasi-
experimental; electronic vs. nonelectronic; pre-order education vs. postorder feedback; 
decreased costs vs. no effect.  
We used the definition of trial designs found in the textbook Foundations of 
Clinical Research : Applications to Practice6 to categorize the studies included in this 
review. Accordingly, we categorized as “experimental” any study in which subjects were 
randomly assigned to at least two comparison groups. We categorized as “quasi-
experimental” those studies that lacked either random assignment at the subject level or 
lacked comparison groups entirely.  
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Our decision to include the category of intervention medium reflects our interests, 
as informaticists, in exploring the impact of electronic tools on clinical care. We 
categorized as “electronic” any intervention in which the primary communication of cost-
related information was presented electronically. We included in the “nonelectronic” 
category studies in which the cost-associated information was presented in a 
nonelectronic format (e.g., lecture, printed price lists, etc.). 
 We included intervention timing in our analysis because it is considered to be one 
of the key factors contributing to the effectiveness of clinical decision support7,8. We 
categorized as “pre-order education” any study in which the content of the intervention 
consisted of generalized cost information (e.g., the price of drug irrespective of whether 
or not it had been ordered by the provider). We categorized as “postorder feedback” any 
intervention consisting of information reflecting costs associated with actual decisions by 
a provider or group of providers. 
We measured interrater agreement for each category using Cohen’s unweighted κ 
statistic. The reviewers resolved disagreements by discussion. Any remaining uncertainty 
was resolved through consensus of all authors. 
Data analysis 
We assessed the relationship between each explanatory variable and the outcome 
(defined as the primary measure of the study or, if the primary measure was not explicitly 
stated, significant decrease in cost or utilization of at least 50% of the items studied) by 
calculating binomial proportion confidence intervals using the Wilson score interval 
approach for individual success rates and the two-sample t test with equal variances 
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method for differences in success rates. We performed the calculations using Stata9 
release 13.1 (StataCorp, College Station, TX).
  
RESULTS 
Our literature search resulted in a total of 4,906 unique references. After screening 
titles and abstracts, we reviewed 41 full-text articles, of which 23 met all of our inclusion 
and exclusion criteria (Figure 1).10-32 Interrater agreements were satisfactory for study 
selection and data abstraction (Table 1). 
Date of publication 
Most (52%) of the studies included in our final analysis were published during or 
after 1999.14-19,23,25,27-30 The earliest study was published in 1982.13 The number of 
publications over time maintained a steady trend, with the exception of a gap from the 
years 2003 to 2009. Only one of the articles that were excluded during full-text review 
was published during this time period. 
Study design 
Seventy percent (16/23) of the studies employed quasi-experimental 
designs12,13,15,17-20,22-28,30,32, lacking the randomization or comparison groups that are 
characteristic of experimental designs.6 The most common of these was the one-group 
pretest-posttest design, used by 6 of the 23 studies that were included in the final 
analysis.18,20,23,28,30,32 Only 30% (7 of 23) of the included studies utilized true 
experimental designs.10,11,14,16,21,29,31 Four studies were classic randomized controlled 















Interrater Agreement for Study Selection and Data Abstraction 
Decision evaluated Raw agreement (%) Cohen’s  κ  (%) 
Study meets all inclusion 
and exclusion criteria based 
on examination of full text 
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calculated the difference between pretest and posttest measurements for each group, and 
compared the calculated differences of the intervention and control groups. The other 
three experimental studies used posttest-only control group designs.10,11,29 
Medium of communication 
In most (70%) of the studies, financial information was presented 
nonelectronically.11-13,15,17,18,20-22,24-30 Nonelectronic media included lecture, information 
posted in common areas, written reference material provided to individuals, information 
listed on prescription forms, printed results that were collected via information systems, 
and personal communication. Thirty percent of the studies utilized electronic 
computerized physician order entry (CPOE) systems to display financial information next 
to orders for tests or therapies.10,14,16,19,23,31,32 
Timing of communication 
Financial information was presented prior to the placement of the clinical order 
(“pre-order education”) in 59% (13 of 22) of the studies.10,14-20,23,25,27,28,32 The timing of 
pre-order education varied from weeks prior to an order to simultaneous presentation at 
the time of the order. Forty-one percent (9 of 22) of studies presented financial 
information following placement of an order (“postorder feedback”).11-13,21,22,24,26,30,31 
Timing of postorder feedback ranged from immediate feedback via computerized 
interface to one week following the placement of an order. One study employed both pre-
order education and postorder feedback communication methods in the intervention 
groups and was excluded from statistical analysis.29 That study showed no significant 
decrease in costs due to the intervention.
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 Impact on cost 
The majority of studies (70%; 16 of 23) demonstrated that cost transparency 
resulted in a decrease in cost and/or utilization.11-13,15-18,21,22,24-28,30,31 Thirty percent (7 of 
23) of the trials did not significantly lower cost or utilization.10,14,19,20,23,29,32 Our 
assessment differed from the conclusion of only one study.19 In that study, the authors 
performed separate statistical analysis for each of the 27 tests included in their 
investigation. Five tests (19%) of the tests showed a statistically significant decrease in 
costs, while the remaining 22 tests showed no significant change from the control group. 
We categorized this result as “no effect” as per our criteria. 
Relationship between explanatory variable and cost 
Table 2 summarizes the success rates of cost transparency interventions, 
categorized by each explanatory variable. The largest rate difference between success 
rates was seen between media for communication (Figure 2). The vast majority (87.5%) 
of interventions that utilized nonelectronic methods for communicating cost information 
to providers reduced costs, whereas only 28.6% of studies providing cost information via 
a computerized physician order entry (CPOE) system showed a similar result (rate 
difference 58.9% (0.22-0.96; p = 0.0031)). Remarkably, 100% of interventions in which 
financial information was provided as feedback after the clinical action resulted in 
decreased costs and/or utilization (Figure 3). In contrast, only 53.8% of cost transparency 
strategies that presented financial information prior to the placement of an order 
decreased costs (rate difference 46.2% (0.098-0.83; p = 0.015)). 
As expected, quasi-experimental studies were slightly more likely to succeed than 
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difference 17% (-0.27-0.63; p = 0.41)). Further analysis revealed a clear trend toward 
pre-order education strategies for cost transparency over time (Figure 4). All of the 
studies published prior to 1990 (4 of 4) used a postorder feedback method for 
communication of cost information. A majority of the studies (55.6%, 5 of 9) published 
between 1990 and 1999, and 90% of studies published after 1999 utilized a pre-order 
education strategy, although one of the studies published after 1999 also incorporated a 
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DISCUSSION 
We systematically reviewed the medical literature to determine the impact of cost 
transparency on provider behavior and the cost of care. We specifically considered the 
effect of two characteristics of the cost transparency interventions: timing and medium of 
communication.  We discovered that interventions in which communication occurred as 
feedback after the clinical decision had been made were significantly more likely to 
succeed than interventions that relied on education prior to the clinical decision. 
Importantly, we observed a clear shift from postorder feedback to pre-order education 
strategies over time, which, according to our results, indicates a shift from a more 
effective method to a less effective method of cost communication. 
We also found that communication via nonelectronic media was more likely to 
reduce cost than communication via electronic CPOE. It is important to note that all of 
the studies included in our analysis that utilized “electronic” media did so through CPOE. 
The inefficacy of electronic communication, therefore, cannot be extended to other 
electronic media such as physician access to automatically generated reports or 
communication of financial outcomes via email. 
We find it noteworthy that the only study using electronic communication for a 
postorder feedback approach (by displaying the cost information in the CPOE 
immediately following the clinical decision) was one of only two “electronic” studies that 
were successful at reducing costs. Although six of the seven “electronic” studies
18 
 
employed a pre-order education approach, the success rate of “electronic” studies is 
lower than that of “pre-order education” studies, suggesting a possible combination of 
unfavorable factors. 
It seems to us that a common element exists between postorder feedback and 
nonelectronic intervention strategies. That common element is personal involvement. 
Nonelectronic communication often involved personal communication. Even in the cases 
in which communication was not directly personal, it may be that information printed on 
paper suggests personal involvement more so than information presented on a computer 
screen. Similarly, postorder feedback suggests that another person has seen and 
potentially evaluated the information as part of the communication process, whereas pre-
order education does not. 
We conjecture that personal involvement in cost transparency interventions has, 
historically, been the key factor in the success of the intervention because it has provided 
an incentive to use the financial information that is made available. Without personal 
involvement, that motivation may not exist. Health care providers are not trained to 
consider financial information in making clinical decisions, and many believe that it is 
inappropriate to do so. In addition, it is widely recognized that the fee-for-service 
payment structure incentivizes utilization to maximize revenue, despite evidence of 
overutilization in many areas of care. Personal involvement conveys accountability for 
costs incurred, thereby encouraging providers to consider costs when making decisions. 
This, of course, is a driving factor behind the formation of accountable care 
organizations. We support the idea that health care providers should work together with 
patients to determine the best course of action for each patient, taking into account 
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financial information, clinical evidence, and personal goals of the patient, sharing 
accountability with the patient for the ultimate outcome. 
Strengths and limitations of our study 
Our study has several strengths. First, our literature search was very thorough, 
with no constraints on the date of publication and including screens of reference lists and 
articles citing every publication that we identified as potentially relevant based. Second, 
we used two reviewers to increase the reliability of study selection and data abstraction. 
Third, we provided a quantitative analysis to assess the impact of each selected 
intervention characteristic on the probability of success. 
One limitation of our study is the narrow focus on cost transparency, which 
excluded broad interventions that involved communication of other information that is 
useful for decision-making, such as quality or outcomes data. We believe that this 
limitation was necessary to isolate the effects of financial information on the cost of care 
delivery. We considered the possibility that limitation may have selectively excluded 
recent publications in which more sophisticated information systems were used to deliver 
both quality and financial information, thereby explaining the shift from postorder 
feedback to pre-order education methods over time, but our analysis revealed that most of 
the studies involving mixed interventions were published in the 1990s. 
Another limitation of our study is the use of binomial outcome measures, 
precluding analysis of effect size. We believe that binomial analysis was appropriate in 
this case considering the relative scarcity and heterogeneity of cost transparency research. 




Finally, our analysis relied on statistical correlation and may therefore have 
identified factors related to, but not causative of, decreased costs of care delivery. For 
example, we did not take into account changes in billing practices, perception of 
malpractice risk, patient expectations, or other cultural changes that may have occurred 
over the course of time. 
Future directions 
The literature describing the effects of cost transparency is sparse. Rigorous 
randomized control trials are necessary to corroborate our findings and determine the 
optimal medium and timing of communication of cost information to health care 
providers.  Additionally, studies assessing the impact of nonCPOE electronic methods of 
cost transparency are needed. Finally, additional research should investigate the 
effectiveness of cost transparency in the context of accountable care organizations or 
other environments in which providers are incented to reduce the cost of care delivery.
  
APPENDIX 
Cost Transparency Search Strategy (Scopus) 
((TITLE-ABS-KEY(("health care" cost*) OR ("health care" fee) OR ("health 
care" economic*) OR ("health care" charge*) OR ("health care" expenditur*) OR 
(healthcare cost*) OR (healthcare fee) OR (healthcare economic*) OR (healthcare 
charge*) OR (healthcare expenditur*) OR (hospital cost*) OR (hospital fee) OR (hospital 
economic*) OR (hospital charge*) OR (hospital expenditur*)) AND (TITLE-ABS-
KEY(control* OR reduc* OR decreas* OR saving OR transparenc* OR cutting OR 
analy*)) AND (TITLE-ABS-KEY(physician* OR clinician* OR doctor* OR provider*)) 
AND (TITLE-ABS-KEY(("practice pattern") OR behavio* OR attitud* OR decision* 
OR awareness* OR knowledg*))) ()) AND (LIMIT-TO(SUBJAREA, "MEDI")) AND 
(LIMIT-TO(DOCTYPE, "ar")) AND (LIMIT-TO(LANGUAGE, "English")) AND 
(LIMIT-TO(EXACTKEYWORD, "Physician's Practice Patterns") OR LIMIT-





1. Sisko AM, Keehan SP, Cuckler GA, et al. National health expenditure 
projections, 2013-23: Faster growth expected with expanded coverage and 
improving economy. Health Aff (Millwood). 2014. 
2. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic 
review. PLoS Med. 2007;4(9):e283. 
3. Cutler D, Dafny L. Designing transparency systems for medical care prices. N 
Engl J Med. 2011;364(10):894-895. 
4. Sinaiko AD, Rosenthal MB. Increased price transparency in health care--
challenges and potential effects. N Engl J Med. 2011;364(10):891-894. 
5. Beilby JJ, Silagy CA. Trials of providing costing information to general 
practitioners: A systematic review. Med J Aust. 1997;167(2):89-92. 
6. Portney LG, Watkins MP. Foundations of clinical research : Applications to 
practice. 3rd ed. Upper Saddle River, N.J.: Pearson/Prentice Hall; 2009. 
7. Bates DW, Kuperman GJ, Wang S, et al. Ten commandments for effective 
clinical decision support: Making the practice of evidence-based medicine a 
reality. J Am Med Inform Assoc. 2003;10(6):523-530. 
8. Campbell R. The five "rights" of clinical decision support. J AHIMA. 
2013;84(10):42-47; quiz 48. 
9. StataCorp. Stata [computer program] rCS, TX: StataCorp LP; 2013. 
10. Bates DW, Kuperman GJ, Jha A, et al. Does the computerized display of charges 
affect inpatient ancillary test utilization? Arch Intern Med. 1997;157:2501-2508. 
11. Berman MF, Simon AE. The effect of a drug and supply cost feedback system on 
the use of intraoperative resources by anesthesiologists. Anesth Analg. 
1998;86:510-515. 
12. Berwick DM, Coltin KL. Feedback reduces test use in a health maintenance 
organization. Journal of the American Medical Association. 1986;255:1450-1454. 
23 
 
13. Cohen DI, Jones P, Littenberg B, Neuhauser D. Does cost information availability 
reduce physician test usage? A randomized clinical trial with unexpected findings. 
Medical Care. 1982;20:286-292. 
14. Durand DJ, Feldman LS, Lewin JS, Brotman DJ. Provider cost transparency alone 
has no impact on inpatient imaging utilization. J Am Coll Radiol. 2013;10:108-
113. 
15. Ellemdin S, Rheeder P, Soma P. Providing clinicians with information on 
laboratory test costs leads to reduction in hospital expenditure. South African 
Medical Journal. 2011;101:746-748. 
16. Feldman LS, Shihab HM, Thiemann D, et al. Impact of providing fee data on 
laboratory test ordering: A controlled clinical trial. JAMA Internal Medicine. 
2013;173:903-908. 
17. Guterman JJ, Chernof BA, Mares B, Gross-Schulman SG, Gan PG, Thomas D. 
Modifying provider behavior: A low-tech approach to pharmaceutical ordering. 
Journal of General Internal Medicine. 2002;17:792-796. 
18. Hampers LC, Cha S, Gutglass DJ, Krug SE, Binns HJ. The effect of price 
information on test-ordering behavior and patient outcomes in a pediatric 
emergency department. Pediatrics. 1999;103:877-882. 
19. Horn DM, Koplan KE, Senese MD, Orav EJ, Sequist TD. The impact of cost 
displays on primary care physician laboratory test ordering. J Gen Intern Med. 
2013;29:708-714. 
20. Horrow JC, Rosenberg H. Price stickers do not alter drug usage. Can J Anaesth. 
1994;41:1047-1052. 
21. Marton KI, Tul V, Sox Jr HC. Modifying test-ordering behavior in the outpatient 
medical clinic. A controlled trial of two educational interventions. Archives of 
Internal Medicine. 1985;145:816-821. 
22. McNitt JD, Bode ET, Nelson RE. Long-term pharmaceutical cost reduction using 
a data management system. Anesth Analg. 1998;87:837-842. 
23. Ornstein SM. Medication cost information in a computer-based patient record 
system impact on prescribing in a family medicine clinical practice. Archives of 
Family Medicine. 1999;8:118-121. 
24. Pugh JA, Frazier LM, DeLong E, Wallace AG, Ellenbogen P, Linfors E. Effect of 
daily charge feedback on inpatient charges and physician knowledge and 
behavior. Archives of Internal Medicine. 1989;149:426-429. 
24 
 
25. Roth EJ, Plastaras CT, Mullin MS, Fillmore J, Moses ML. A simple institutional 
educational intervention to decrease use of selected expensive medications. 
Archives of Physical Medicine and Rehabilitation. 2001;82:633-636. 
26. Sachdeva RC, Jefferson LS, Coss-Bu J, et al. Effects of availability of patient-
related charges on practice patterns and cost containment in the pediatric intensive 
care unit. Crit Care Med. 1996;24:501-506. 
27. Schilling UM. Cutting costs: The impact of price lists on the cost development at 
the emergency department. Eur J Emerg Med. 2010;17:337-339. 
28. Seguin P, Bleichner J, Grolier J, Guillou Y, Mallédant Y. Effects of price 
information on test ordering in an intensive care unit. Intensive Care Medicine. 
2002;28:332-335. 
29. Sommers BD, Desai N, Fiskio J, et al. An educational intervention to improve 
cost-effective care among medicine housestaff: A randomized controlled trial. 
Academic Medicine. 2012;87:719-728. 
30. Stuebing EA, Miner TJ. Surgical vampires and rising health care expenditure: 
Reducing the cost of daily phlebotomy. Arch Surg. 2011;146:524-527. 
31. Tierney WM, Miller ME, McDonald CJ. The effect on test ordering of informing 
physicians of the charges for outpatient diagnostic tests. N Engl J Med. 
1990;322:1499-1504. 
32. Vedsted P, Nielsen JN, Olesen F. Does a computerized price comparison module 
reduce prescribing costs in general practice? Fam Pract. 1997;14:199-203. 
 
